Skip to content

Novavax NVAX Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Moderna logo
ModernaMRNA
$150M
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$61K
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$400M
LQD
Liquidia CorporationLQDA
$0-100%

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromLinesOfCredit.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's debt issuance proceeds?
Novavax (NVAX) reported debt issuance proceeds of $46.41M in Q1 2026.
What does debt issuance proceeds mean?
Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.